The survival of patients with multiple myeloma has improved tremendously over the years. However, patients with disease that has relapsed and is refractory to thalidomide, lenalidomide and bortezomib have poor long-term outcomes. The novel immunomodulatory drug pomalidomide now offers a new therapeutic option for these patients.
